Supplementary Table 1: Change in CD4+ cell count in trials comparing rilpivirine-(RPV)-based regimens with other antiretroviral therapies (ART).

Study

RPV group

Comparator [p value*]

Treatment-naïve patients

TMC278-C204

Pozniak 2010 [33]

48-week (RPV 25 mg/day arm)

Change from BL (cells/µL), mean (SE), median

122.1 (11.8), 108

96-week (RPV 25 mg/day arm)

Change from BL (cells/µL), mean (SE), median

145.8 (12.1), 138

48-week (RPV 25 mg/day arm)

Change from BL (cells/µL), mean (SE), median

126.5 (11.1), 120.5

96-week

Change from BL (cells/µL), mean (SE), median

159.8 (13.4), 170.5

ECHO & THRIVE

Cohen 2012 [36]

(ECHO & THRIVE week 48 results)

Cohen 2013 [5] (ECHO & THRIVE week 96 results)

48-week

Change from BL (cells/mm3), mean (95% CI)

192 (181-203)

96-week

Change from BL (cells/µL), mean (95% CI)

228 (215-240)

48-week

Change from BL (cells/mm3), mean (95% CI)

176 (165-188)

96-week

Change from BL (cells/µL), mean (95% CI)

219 (206-233)

STAR

Cohen 2014 [32] (week 48 results)

Van Lunzen 2016 [7] (week 96 results)

48-week

Change from BL (cells/µL), mean (SD)

200 (159)

96-week

Change from BL (cells/µL), mean (SD)

178 (189)

48-week

Change from BL (cells/µL), mean (SD)

191 (144)

96-week

Change from BL (cells/µL), mean (SD)

259 (191)

Treatment-experienced, virologically controlled patients

SPIRIT

Palella 2014 [10]

48-week

Change from BL (cells/µL), mean 10

48 week

Change from BL (~ 24 weeks BL ART & 24 weeks RPV + FTC + TDF) (cells/µL), mean -7

LATTE

Margolis 2015 [28]

48-week: 24-week induction (no RPV) + 24-week RPV

Change from BL° (cells/µL), median (q1, q3)

219 (141, 343)

72-week: 24-week induction (no RPV) + 48-week RPV

Change from BL° (cells/µL), median (q1, q3)

205 (117, 339)

96-week: 24-week induction (no RPV) + 72-week RPV

Change from BL° (cells/µL), median (q1, q3)

259.5 (137, 355)

24-week induction (no RPV) + 24-week RPV

Change from BL° (cells/µL), median (q1, q3)

216 (133.5, 363)

72 week: 24-week induction (no RPV) + 48-week RPV

Change from BL° (cells/µL), median (q1, q3)

208.5 (94, 355)

96 week: 24-week induction (no RPV) + 72-week RPV

Change from BL° (cells/µL), median (q1, q3)

289 (158, 415)

Probe

Maggiolo 2016 [11]

48-week

Change from BL (cells/µL), mean (SD)

15 (184)

48-week

Change from BL (cells/µL), mean (SD)

16 (142)

GS-US-366-1160

DeJesus 2017 [34] (week 48 results)

Hagins 2018 [12] (week 96 results)

48-week

Change from BL (cells/µL), mean (SD)

23 (156)

96-week

Change from BL (cells/µL), mean (SD)

12 (199.8)

48-week

Change from BL (cells/µL), mean (SD)

12 (153) [p = 0.31]

96-week

Change from BL (cells/µL), mean (SD)

6 (153.2) [p = 0.64]

SWORD-1 & SWORD-2

Llibre 2018 [9] (week 48 results)

Aboud 2019 [8] (week 100 results)

48-week

Change from BL (cells/µL), median (q1, q3)

28 (-55, 112.5)

100-week

Change from BL (cells/µL), median (q1, q3)

33 (-51, 148)

48-week

Change from BL (cells/µL), median (q1, q3)

22 (-46, 108)

100-week

Change from the late-switch BL (~ 48 week of RPV + DTG) (cells/µL), median (q1, q3)

13 (-78, 98)

SALIF

Munderi, et al. 2019 [13]

48-week

Change from BL (cells/mm3), mean (SD)

26.2 (125.1)

48-week

Change from BL (cells/mm3), mean (SD)

6.1 (140.1)

Petchkum 2019 [14]

48-week

BL - week 48 (cells/mm3), median (q1, q3)

563 (457, 727) - 547 (417, 708)

48-week

BL - week 48 (cells/mm3), median (q1, q3)

552 (434, 733) [p = 0.912] - 520 (424, 720) [p = 0.911]

Abbreviations: BL: Baseline; DTG: Dolutegravir; RPV: Rilpivirine.

*for comparison with the RPV group, as reported in the publication.

°at study baseline, patients were treatment-naïve.